preclinical considerations for cell and gene therapy products, an fda perspective
Published 3 years ago • 17K plays • Length 46:52Download video MP4
Download video MP3
Similar videos
-
36:56
fda’s clinical regulatory perspective: designing first-in-human trial for cellular and gene therapy
-
29:42
cmc considerations for car t cell product development
-
3:17
a new fda-approved gene therapy helps treat a rare childhood cancer
-
7:56:19
cellular, tissue, and gene therapies advisory committee (ctgtac) meeting - day 1
-
22:36
regulatory considerations for cell and gene therapies - jim dekloe
-
8:39:50
75th cellular, tissue, and gene therapies advisory committee
-
9:26:46
74th cellular, tissue, and gene therapies advisory committee
-
43:14
introduction to regulatory science at the fda
-
18:21
assembling the best team to navigate through preclinical development
-
10:22
3/21/2016 - fda perspective
-
1:10:23
fda clinical investigator training course (citc) 2022, day 1 – part 3
-
2:44
fda panel to vote on revolutionary gene therapy for cancer
-
25:56
advanced topics successful development of quality cell and gene therapy products
-
6:24:21
73nd cellular, tissue and gene therapies advisory committee - day 1
-
31:53
getting to first-in-human for small molecules and biologics
-
1:01
fda approves novartis gene therapy for rare genetic disorder
-
17:53
media call: fda approves first gene therapies to treat sickle cell disease – 12/08/2023
-
43:56
site design considerations for cell and gene therapy commercial facilities
-
36:21
3/21 mrt public discussion meeting: presentations (fda perspective and committee overview)